These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 10144008

  • 1. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 2. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007 Jul; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 3. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003 Jul; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 4. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 5. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000 Dec; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 6. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M.
    N Engl J Med; 2006 Sep 28; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract] [Full Text] [Related]

  • 7. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Sep 28; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 8. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 9. Biotech industry struggles with generics approval.
    Knight J.
    Nature; 2004 Jun 10; 429(6992):588. PubMed ID: 15190316
    [No Abstract] [Full Text] [Related]

  • 10. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA.
    J Contemp Health Law Policy; 1992 Jun 10; 8():361-78. PubMed ID: 10118987
    [No Abstract] [Full Text] [Related]

  • 11. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B.
    BMJ; 2012 Dec 12; 345():e8464. PubMed ID: 23236054
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE.
    J Health Econ; 2011 Jan 12; 30(1):126-45. PubMed ID: 21074873
    [Abstract] [Full Text] [Related]

  • 14. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov 28; 62(229):63268-9. PubMed ID: 10177950
    [Abstract] [Full Text] [Related]

  • 15. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA.
    Mich Law Rev; 2009 Oct 28; 108(1):37-80. PubMed ID: 20535881
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM.
    Fordham Law Rev; 2006 Dec 28; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract] [Full Text] [Related]

  • 18. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 Dec 28; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 19. Countering delays in introduction of generic drugs.
    Lancet; 2002 Jan 19; 359(9302):181. PubMed ID: 11812545
    [No Abstract] [Full Text] [Related]

  • 20. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Jan 19; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.